Sahu Tarun, Verma Henu Kumar, Bhaskar Lakkakula V K S
Department of Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, India.
Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 85764, Germany.
World J Virol. 2022 Mar 25;11(2):107-110. doi: 10.5501/wjv.v11.i2.107.
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4 T and CD8 T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections.
微生物合并感染是2019冠状病毒病（COVID-19）患者的另一个主要问题，但它在研究人员中仍是一个未被触及的领域。初步数据和系统评价仅显示了造成这种情况的病原体类型，但其病理生理学仍不清楚。研究表明，这些微生物合并感染是医院获得性/医院感染，入住重症监护病房并接受有创机械通气的患者极易感染。COVID-19患者的炎性细胞因子升高，细胞介导的免疫反应减弱，CD4 T细胞和CD8 T细胞计数较低，表明易发生各种合并感染。尽管如此，只有少数研究对合并感染的管理提出了建议。
